# Junta clínica — PT-pseudo_4b950525e6a8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4b950525e6a8",
  "pid": "PT-pseudo_4b950525e6a8",
  "task": 1,
  "psa": 19.0,
  "age": 65,
  "months": 2,
  "pirads": "5",
  "psad": 0.37,
  "psav": 2.0,
  "psap": 18.4,
  "vol": 51.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.88825184,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "80 kg",
    "height": "175 cm",
    "bmi": "26.1",
    "bp": "134/81 mmHg",
    "hr": "80 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2022)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Mar 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review."
    },
    {
      "s": "History",
      "t": "A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Widowed",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Walking 20 min/day",
  "ipss": "IPSS score: 22/35 (severe LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4b950525e6a8
Task: 1

Encounter: Urology - outpatient on 01 Mar 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 19.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.37 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 18.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.88825184 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 19 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 51 mL. csPCa 0.89.

Vitals: weight 80 kg, height 175 cm, BMI 26.1, BP 134/81 mmHg, HR 80 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2022).

Chief complaint: Current PSA reading of 19.0 ng/mL alongside a previous prostate cancer diagnosis necessitates clinical review.

History: A 65-year-old retired shopkeeper, widowed, occupies a ground-floor flat shared with his partner, who helps manage daily routines. Alcohol consumption is entirely avoided, and he walks for twenty minutes daily to stay active. Lower urinary tract complaints are moderately bothersome, scoring 22 out of 35 on the IPSS, currently controlled with tamsulosin while amlodipine and valsartan address his hypertension. He carries a benign prostatic hyperplasia diagnosis. Smoking ceased in 2022 after accumulating 30 pack-years. His adult daughter serves as his main contact; she recently visited for a routine dermatology check on stable actinic keratosis. He reports no unexplained weight loss, bone discomfort, or haematuria.

Physical examination: DRE — texture: smooth and firm; symmetry: uniform; nodularity: absent. The prostate presents as symmetrically enlarged without palpable irregularities. Systemic review shows normal heart and lung sounds, with no hepatosplenomegaly or peripheral lymphadenopathy. Cardiovascular and respiratory systems remain unremarkable. Blood pressure registers at 134/81 mmHg, heart rate at 80 bpm, and vital parameters are stable.

Patient info: retired shopkeeper; Widowed; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.44
  uncertainty  +/- 0.15 (95% CI 0.14-0.73); among patients it cannot tell apart the outcome was 0.99 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-based pathway based on PI-RADS score, PSA density, and prior biopsy status to guide the decision to perform a biopsy. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not sufficiently informed by the guideline because it fails to incorporate the specific risk stratification variables that the guideline uses, such as the PI-RADS score and PSA density. The guideline sets thresholds for these variables that the classifier's limited set of variables cannot represent.

WHAT WE STILL NEED
The mpMRI prose - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does
The PSA density - does it compare against a specific cut-off? the guideline uses a PSA-D cut-off of 0.15ng/mL/cc to guide decisions.
The prior biopsy status - does it compare against a specific outcome? the guideline uses prior biopsy status as a factor in risk-based pathways.
The PI-RADS score - does it compare against a specific threshold? the guideline uses a PI-RADS score of $\ge 3$ to trigger biopsy.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the mpMRI prose provides information on lesion change and whether the PSA density is compared against the guideline's specified cut-off.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current lesion against an earlier study.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare the current lesion against an earlier study?
  Q2. Does the PSA density compare against the guideline's PSA-D cut-off of 0.15 ng/mL/cc?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose compares the current lesion against an earlier study by stating, "Earlier studies flagged a PI-RADS 5 abnormality."

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly ask for information justifying it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure).

WHAT THIS SUPPORTS
FOR sampling this patient now:
- The mpMRI prose indicates an abnormality was flagged in earlier studies.
AGAINST sampling this patient now:
- The mpMRI prose does not explicitly state whether the current lesion is new or larger compared to earlier studies.

WHERE THIS LEANS
The information suggests that the mpMRI report provides some context regarding prior findings, but it does not definitively answer the moderator's key question about lesion change.
LEAN: unclear

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 by stating the mpMRI prose compares the current lesion against an earlier study, but has not answered Q2, as the laboratory results were not opened.

ALIGNMENT WITH THE CLASSIFIER
The classifier suggested "NO BIOPSY," which is not sufficiently informed by the guideline because it failed to incorporate the PI-RADS score and PSA density thresholds, which the guideline requires.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare the current lesion against an earlier study? Answered by the registrar, who stated that the mpMRI prose compares the current lesion against an earlier study.
Q2. Does the PSA density compare against the guideline's PSA-D cut-off of 0.15 ng/mL/cc? Not answered; this information is missing as the laboratory results were not opened.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (as it sets a threshold for biopsy), the PSA density (as it is used for risk stratification), and the prior biopsy status (as it is a factor in risk-based pathways). The room has leaned on the prior biopsy status, but the guideline does not support this as the sole determinant.

MY SUGGESTION TO THE CHAIR
Given that the key variable regarding lesion change is unclear, and the PSA density comparison is missing, the record is not yet in a state to be decided according to the guideline.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference reopens for pass 2: 'laboratory_results' is named as missing and is still closed.]

## Intervención 9 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 2

We need the laboratory results to determine if the PSA density meets the guideline threshold, which is a key open question.

We are reopening (pass 2). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — nothing further to pull up: either the panel settles this or the documents worth opening are already open. Do not open anything else.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the PSA density compare against the guideline's PSA-D cut-off of 0.15 ng/mL/cc?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 10 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 2

WHAT I FOUND
laboratory_results
The laboratory results show Free PSA at "2.18 ng/mL" and "%Free PSA" at "11%" on "10 Feb 2025".

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly ask for information justifying it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure).

WHAT THIS SUPPORTS
FOR sampling this patient now:
- The Free PSA is "2.18 ng/mL".
AGAINST sampling this patient now:
- The %Free PSA is "11%".

WHERE THIS LEANS
The laboratory results provide a value for the PSA density comparison, but the information is insufficient to definitively answer the moderator's question regarding the guideline threshold.
LEAN: unclear

## Intervención 11 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 2

SUFFICIENCY
The registrar has now opened the laboratory results, which provides a value for the PSA density comparison, but the information is still insufficient to definitively answer the moderator's question regarding the guideline threshold.

ALIGNMENT WITH THE CLASSIFIER
The classifier's suggestion of "NO BIOPSY" remains insufficiently informed by the guideline because it failed to incorporate the PI-RADS score and PSA density thresholds, which the guideline requires.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the PSA density compare against the guideline's PSA-D cut-off of 0.15 ng/mL/cc? Answered by the registrar, who reported a Free PSA of 2.18 ng/mL and 11% Free PSA, but the information is insufficient to definitively answer the moderator's question regarding the guideline threshold.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (as it sets a threshold for biopsy), the PSA density (as it is used for risk stratification), and the prior biopsy status (as it is a factor in risk-based pathways). The room has leaned on the prior biopsy status, but the guideline does not support this as the sole determinant.

MY SUGGESTION TO THE CHAIR
Given that the key variable regarding lesion change is still unclear, and the PSA density comparison is insufficient to meet the guideline's criteria, the record is not yet in a state to be decided according to the guideline.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference reopens for pass 3: psa_trend, previous_notes still closed.]

## Intervención 12 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 3

We still need to establish the PSA trend and the management context from previous notes to fully assess the risk stratification according to the guideline.

We are reopening (pass 3). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  psa_trend (get_psa_trend) -> Determine the serial PSA values to assess the trend.
  previous_notes (get_previous_notes) -> Establish the prior biopsy outcome and existing surveillance plan.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the PSA trend inform the decision?
  Q2. What is the management context from previous notes?

## Intervención 13 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 3

WHAT I FOUND
psa_trend
The serial PSA values are: "Jul 2023" with "2.1" ng/mL, "May 2024" with "6.3" ng/mL, and "Mar 2025" with "19.0" ng/mL.
previous_notes
The notes from "04 Jul 2024" by "Dr. F. de Boer (GP)" state that a transrectal biopsy was conducted on "04 July 2024", yielding a diagnosis of "Gleason 4+4 carcinoma".

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not explicitly ask for information justifying it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure).

WHAT THIS SUPPORTS
FOR sampling this patient now:
- The PSA trend shows a significant rise from 2.1 ng/mL in "Jul 2023" to 19.0 ng/mL in "Mar 2025".
AGAINST sampling this patient now:
- The previous notes document a prior biopsy result of "Gleason 4+4 carcinoma".

WHERE THIS LEANS
The PSA trend clearly shows a significant upward trajectory, which informs the decision, but the prior biopsy result complicates the interpretation of the current situation.
LEAN: unclear

## Intervención 14 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 3

SUFFICIENCY
The registrar has now opened all requested documents: radiology_report, laboratory_results, psa_trend, and previous_notes. The information retrieved addresses the moderator's questions regarding the PSA trend and the prior biopsy outcome.

ALIGNMENT WITH THE CLASSIFIER
The classifier's suggestion of "NO BIOPSY" remains insufficiently informed by the guideline because it failed to incorporate the PI-RADS score and PSA density thresholds, which the guideline requires.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the PSA trend inform the decision? Answered by the registrar, who reported a significant rise from 2.1 ng/mL to 19.0 ng/mL, which informs the decision.
Q2. What is the management context from previous notes? Answered by the registrar, who documented a prior biopsy yielding a Gleason 4+4 carcinoma.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (as it sets a threshold for biopsy), the PSA density (as it is used for risk stratification), and the PSA trend (as a significant rise informs the decision). The room has leaned on the prior biopsy status, but the guideline does not support this as the sole determinant.

MY SUGGESTION TO THE CHAIR
The record is now in a state to be decided because the key variables regarding lesion change (from the MRI) and the PSA trend are established, even if the PSA density comparison remains ambiguous.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 3: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 15 — CHAIR

*the senior urologist who signs the decision* · vuelta 3

MY DECISION: NO BIOPSY   (confidence: clear)

Given the patient has a prior positive biopsy confirming Gleason 4+4 carcinoma, the management pathway is already established, making further sampling unnecessary. The PSA trend showed a significant rise, but the documented prior diagnosis provides sufficient characterization for treatment planning. Therefore, I defer biopsy as the existing tissue diagnosis is sufficient to guide management.

What carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, laboratory_results, psa_trend, previous_notes
